https://doi.org/10.4081/aiua.2025.13645
The effect of flavonoid and subclasses supplementation on prostate specific antigen, hormonal parameters and prostate cancer risk: a systematic review and meta-analysis of randomized controlled trials
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 17 April 2025
Introduction and objectives: Prostate cancer (PCa) is a significant concern and burden worldwide. Several studies suggest that flavonoids have a significant potential as an anti-cancer agent, but the evidence remains controversial. This study aims to assess the effect of flavonoids and its subclasses supplementation on PCa risk parameters in men with biopsy-proven diagnosis of PCa or clinically determined to have a high risk of PCa.
Materials and methods: This systematic review and meta-analysis adhered to PRISMA guideline. A literature search was conducted across PubMed, ScienceDirect, Scopus and Cochrane utilizing PICO framework. Revised Cochrane’s risk of bias tools (RoB2) was used for quality analysis. Review manager 5.4 was used for statistical analysis.
Results: Out of 1.117 articles, nine final studies (involving 420 patients) were included. Regarding total PSA, flavonoid provided a reduction of total PSA (MD: -0.64, p<0.05), and sub-group analysis based on the supplementation duration showed flavonoid administration with a duration of ≥12 weeks significantly reduced total PSA compared to administration of <12 weeks (p<0.05). Meta-analyses of four studies, including men clinically at risk of PCa, revealed that flavonoid supplementation was associated with a significantly lower risk of developing PCa at endpoint (OR 0.41, p<0.05). However, our results indicated no favorable effect on hormonal parameters.
Conclusions: The results of this meta-analysis suggest there may be a potential role for flavonoid in PCa risk reduction. Flavonoids supplementation also have been proven to be safe. However, further investigation is necessary to gain a clear understanding of the flavonoid impact on PSA and sex hormone parameters.
Downloads
Tzelepi V. Prostate cancer: pathophysiology, pathology and therapy. Cancers. 2022; 15:281. DOI: https://doi.org/10.3390/cancers15010281
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89. DOI: https://doi.org/10.14740/wjon1191
Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022; 27:5730. DOI: https://doi.org/10.3390/molecules27175730
Giona S. The epidemiology of prostate cancer. In: Bott SR, Ng KL (eds) Prostate cancer. Brisbane: Exon Publications.,
Matsushita M, Fujita K, Nonomura N. Influence of diet and nutrition on prostate cancer. Int J Mol Sci. 2020; 21:1447. DOI: https://doi.org/10.3390/ijms21041447
Mirza MB, Elkady AI, Al-Attar AM, et al. Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells. J Ethnopharmacol. 2018;218:35-44. DOI: https://doi.org/10.1016/j.jep.2018.02.030
Dueregger A, Heidegger I, Ofer P, et al. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients. 2014; 6:4491-4519. DOI: https://doi.org/10.3390/nu6104491
Jeong SH, Kim HH, Park MY, et al. Flavones: the apoptosis in prostate cancer of three flavones selected as therapeutic candidate models. Int J Mol Sci. 2023; 24:9240. DOI: https://doi.org/10.3390/ijms24119240
Liskova A, Samec M, Koklesova L, et al. Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA J. 2021; 12:155-176. DOI: https://doi.org/10.1007/s13167-021-00242-5
Galván-Portillo M, Vázquez-Salas RA, Hernández-Pérez JG, et al. Dietary flavonoid patterns and prostate cancer: evidence from a Mexican population-based case-control study. Br J Nutr. 2021;1-9. DOI: https://doi.org/10.1017/S0007114521002646
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021; 372: n160. DOI: https://doi.org/10.1136/bmj.n160
Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-1558. DOI: https://doi.org/10.1002/sim.1186
Kumar NB, Pow-Sang J, Spiess P, et al. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020; 11:1218-1234. DOI: https://doi.org/10.18632/oncotarget.27529
Kumar NB, Krischer JP, Allen K, et al. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007; 59:163-168. DOI: https://doi.org/10.1080/01635580701432678
Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. The Prostate. 2004; 59:141-147. DOI: https://doi.org/10.1002/pros.10362
Dalais FS, Meliala A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology. 2004;64:510-515. DOI: https://doi.org/10.1016/j.urology.2004.04.009
Kumar NB, Pow-Sang J, Egan KM, et al. Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. Cancer Prev Res Phila Pa. 2015; 8:879-887. DOI: https://doi.org/10.1158/1940-6207.CAPR-14-0324
Miyanaga N, Akaza H, Hinotsu S, et al. Prostate cancer chemo- prevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci. 2012; 103:125-130. DOI: https://doi.org/10.1111/j.1349-7006.2011.02120.x
Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer. 2007; 60:7-13. DOI: https://doi.org/10.1080/01635580701586770
Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr. 2007; 137:1769-1775. DOI: https://doi.org/10.1093/jn/137.7.1769
Bosland MC, Schmoll J, Watanabe H, et al. Randomized, placebo-controlled six-month intervention study of soy protein isolate in men with biochemical recurrence after radical prostatectomy: a pilot study. Nutr Cancer. 2022; 74:555-564. DOI: https://doi.org/10.1080/01635581.2021.1903949
Guo K, Liang Z, Liu L, et al. Flavonoids intake and risk of prostate cancer: a meta-analysis of observational studies. Andrologia. 2016; 48:1175-1182. DOI: https://doi.org/10.1111/and.12556
Chang H, Lei L, Zhou Y, et al. Dietary flavonoids and the risk of colorectal cancer: an updated meta-analysis of epidemiological studies. nutrients. 2018; 10:950. DOI: https://doi.org/10.3390/nu10070950
Farha MW, Salami SS. biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol 2022; 14:17562872221103988. DOI: https://doi.org/10.1177/17562872221103988
Ganry O. Phytoestrogens and prostate cancer risk. Prev Med. 2005;41:1-6. DOI: https://doi.org/10.1016/j.ypmed.2004.10.022
van Die MD, Bone KM, Williams SG, et al. Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int. 2014;113:E119-130. DOI: https://doi.org/10.1111/bju.12435
Tanaka M, Fujimoto K, Chihara Y, et al. Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. Prostate Cancer Prostatic Dis. 2009;12:247-252. DOI: https://doi.org/10.1038/pcan.2009.10
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.